A Targeted Literature Review on Medication Adherence: A Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Study

Author(s)

Smith S1, Mendelsohn AB2, Abente E3, Djibo DA3, Kenney JT4, Yee G5, Lockhart C6
1Harvard Pilgrim Health Care Institute, Brighton, MA, USA, 2Harvard Pilgrim Health Care Institute, Boston, MA, USA, 3CVS Health, Blue Bell, PA, USA, 4JAMESTKENNEY LLC, Waltham, MA, USA, 5University of Nebraska Medical Center, Omaha, NE, USA, 6Biologics and Biosimilars Collective Intelligence Consortium, Asheville, NC, USA

OBJECTIVES: To conduct a literature review investigating how adherence and persistence are measured using secondary data.

METHODS: Full text articles (n=1,505) were identified in PubMed, EMBASE, and Web of Science databases using these keywords: compliance, adherence, administrative claims, real-world, observational. Articles were excluded for these reasons: abstract review(n=18), cost/economic analyses (n=36), duplicates (n=136), not healthcare-related (n=23), non-human subjects (n=4), did not discuss adherence (n=488), physiology or pharmacology (n=23), randomized control trials (n=5), reviews/commentary (n=9), protocol only (n=36), technology management (n=2), vaccine adherence (n=13), not secondary data (n=8), focused on predictive models (n=3). Our full text review included 665 articles. For each article, we gathered information on the country where the study took place, drug(s) of interest, disease(s) of interest, which adherence methods were used and how measured, and the data source.

RESULTS: Adherence was measured using the Medication Possession Ratio (MPR) (n=156), defined as the sum of the days’ supply for a drug divided by number of days in a specified period. A cutoff of 80% was applied for categorizing patients as adherent vs. non-adherent. Other methods for assessing adherence included self-reported measures, e.g., the Morisky Green Levine Scale, MARS patient survey, and Kemp’s seven-point scale Persistence was measured through the Proportion of Days Covered (PDC) (n=192), defined as the number of days of use over the total days in a specified period. A cutoff of 80% was used for categorizing patients as persistent vs. non-persistent. Persistence was also measured in relation to drug discontinuation, defined as a gap of more than 30, 60, or 90 days in the utilization of the index drug.

CONCLUSIONS: Across products spanning therapeutic areas and recommended usage patterns, we found consistency with adherence and persistence measurement. We will apply these algorithms to large data sources to explore adherence and persistence for various biologics products.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

EPH92

Topic

Epidemiology & Public Health, Study Approaches

Topic Subcategory

Literature Review & Synthesis, Public Health, Safety & Pharmacoepidemiology

Disease

Biologics & Biosimilars, Drugs

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×